{"id":"W4409097322","doi":"10.1016/s1470-2045(25)00031-2","title":"First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Prostate cancer; Placebo; Medicine; Homologous recombination; Oncology; Internal medicine; Cancer research; Gene; Cancer; Biology; Genetics; Pathology; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001433685,0.001847896,0.003039894,0.0004094609,0.0002623796,0.000983151,0.0009005063,0.001447683,0.005773627],"category_scores_gemma":[0.001530905,0.0005265265,0.002839604,0.0003425974,0.0009548768,0.001104842,0.000401651,0.002889569,0.0006864095],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008567786,"about_ca_system_score_gemma":0.0006347595,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001498877,"about_ca_topic_score_gemma":0.003920845,"domain_scores_codex":[0.999496,0.0002771108,0.0000271714,0.00008358845,0.00003124747,0.00008487336],"domain_scores_gemma":[0.9993394,0.000208846,0.0001781404,0.00004234746,0.00003518347,0.0001961128],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9867632,0.001078319,0.0004286415,0.0005825376,0.001781941,0.0000254092,0.00002703625,0.0003806455,0.0009719678,0.00006205845,0.0006067261,0.007291466],"study_design_scores_gemma":[0.9499143,0.043071,0.003382586,0.00006183709,0.001842747,0.00004881543,0.00004483424,0.0004972803,0.0003338156,0.0001984059,0.0005793685,0.00002499381],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9792364,0.01438779,0.0004425761,0.0009899212,0.0007241775,0.0006107519,0.001332757,0.0001525085,0.002123152],"genre_scores_gemma":[0.9907259,0.003693745,0.0004470775,0.0009442961,0.0003884356,0.0004345301,0.001145302,0.00002127138,0.002199398],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005773627,"threshold_uncertainty_score":0.01931471,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07915377553234595,"score_gpt":0.3870291517432157,"score_spread":0.3078753762108697,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}